Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Subscribe

Logo for

Science 305 (5681): 200-205

Copyright © 2004 by the American Association for the Advancement of Science

Cancer Immunotherapy: A Treatment for the Masses

Joseph N. Blattman, and Philip D. Greenberg*

Abstract: Cancer immunotherapy attempts to harness the exquisite power and specificity of the immune system for the treatment of malignancy. Although cancer cells are less immunogenic than pathogens, the immune system is clearly capable of recognizing and eliminating tumor cells. However, tumors frequently interfere with the development and function of immune responses. Thus, the challenge for immunotherapy is to use advances in cellular and molecular immunology to develop strategies that effectively and safely augment antitumor responses.

Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA, and Departments of Immunology and Medicine, University of Washington, 1959 Northeast Pacific Street, Seattle, WA 98195–6527, USA.

* To whom correspondence should be addressed. E-mail: pgreen{at}u.washington.edu

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients.
A. G. Chapuis, G. B. Ragnarsson, H. N. Nguyen, C. N. Chaney, J. S. Pufnock, T. M. Schmitt, N. Duerkopp, I. M. Roberts, G. L. Pogosov, W. Y. Ho, et al. (2013)
Science Translational Medicine 5, 174ra27
   Abstract »    Full Text »    PDF »
Durable Adoptive Immunotherapy for Leukemia Produced by Manipulation of Multiple Regulatory Pathways of CD8+ T-Cell Tolerance.
M. M. Berrien-Elliott, S. R. Jackson, J. M. Meyer, C. J. Rouskey, T.-L. M. Nguyen, H. Yagita, P. D. Greenberg, R. J. DiPaolo, and R. M. Teague (2013)
Cancer Res. 73, 605-616
   Abstract »    Full Text »    PDF »
BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice.
C. Liu, W. Peng, C. Xu, Y. Lou, M. Zhang, J. A. Wargo, J. Q. Chen, H. S. Li, S. S. Watowich, Y. Yang, et al. (2013)
Clin. Cancer Res. 19, 393-403
   Abstract »    Full Text »    PDF »
Abrogation of Src Homology Region 2 Domain-Containing Phosphatase 1 in Tumor-Specific T Cells Improves Efficacy of Adoptive Immunotherapy by Enhancing the Effector Function and Accumulation of Short-Lived Effector T Cells In Vivo.
I. M. Stromnes, C. Fowler, C. C. Casamina, C. M. Georgopolos, M. S. McAfee, T. M. Schmitt, X. Tan, T.-D. Kim, I. Choi, J. N. Blattman, et al. (2012)
J. Immunol. 189, 1812-1825
   Abstract »    Full Text »    PDF »
The differential production of cytokines by human Langerhans cells and dermal CD14+ DCs controls CTL priming.
J. Banchereau, L. Thompson-Snipes, S. Zurawski, J.-P. Blanck, Y. Cao, S. Clayton, J.-P. Gorvel, G. Zurawski, and E. Klechevsky (2012)
Blood 119, 5742-5749
   Abstract »    Full Text »    PDF »
Activated STAT5 Promotes Long-Lived Cytotoxic CD8+ T Cells That Induce Regression of Autochthonous Melanoma.
M. Grange, M. Buferne, G. Verdeil, L. Leserman, A.-M. Schmitt-Verhulst, and N. Auphan-Anezin (2012)
Cancer Res. 72, 76-87
   Abstract »    Full Text »    PDF »
Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection.
R. D. Aubert, A. O. Kamphorst, S. Sarkar, V. Vezys, S.-J. Ha, D. L. Barber, L. Ye, A. H. Sharpe, G. J. Freeman, and R. Ahmed (2011)
PNAS 108, 21182-21187
   Abstract »    Full Text »    PDF »
Resuscitating Cancer Immunosurveillance: Selective Stimulation of DLL1-Notch Signaling in T cells Rescues T-cell Function and Inhibits Tumor Growth.
Y. Huang, L. Lin, A. Shanker, A. Malhotra, L. Yang, M. M. Dikov, and D. P. Carbone (2011)
Cancer Res. 71, 6122-6131
   Abstract »    Full Text »    PDF »
Cancer Immunotherapy Using a Bispecific NK Receptor Fusion Protein that Engages both T Cells and Tumor Cells.
T. Zhang and C. L. Sentman (2011)
Cancer Res. 71, 2066-2076
   Abstract »    Full Text »    PDF »
A TCR Targeting the HLA-A*0201-Restricted Epitope of MAGE-A3 Recognizes Multiple Epitopes of the MAGE-A Antigen Superfamily in Several Types of Cancer.
N. Chinnasamy, J. A. Wargo, Z. Yu, M. Rao, T. L. Frankel, J. P. Riley, J. J. Hong, M. R. Parkhurst, S. A. Feldman, D. S. Schrump, et al. (2011)
J. Immunol. 186, 685-696
   Abstract »    Full Text »    PDF »
Tumor Ablation by Gene-Modified T Cells in the Absence of Autoimmunity.
L. X. J. Wang, J. A. Westwood, M. Moeller, C. P. M. Duong, W.-Z. Wei, J. Malaterre, J. A. Trapani, P. Neeson, M. J. Smyth, M. H. Kershaw, et al. (2010)
Cancer Res. 70, 9591-9598
   Abstract »    Full Text »    PDF »
Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses.
W. Peng, Y. Ye, B. A. Rabinovich, C. Liu, Y. Lou, M. Zhang, M. Whittington, Y. Yang, W. W. Overwijk, G. Lizee, et al. (2010)
Clin. Cancer Res. 16, 5458-5468
   Abstract »    Full Text »    PDF »
Ligand-Independent Toll-like Receptor Signals Generated by Ectopic Overexpression of MyD88 Generate Local and Systemic Antitumor Immunity.
Z. C. Hartman, T. Osada, O. Glass, X. Y. Yang, G.-j. Lei, H. K. Lyerly, and T. M. Clay (2010)
Cancer Res. 70, 7209-7220
   Abstract »    Full Text »    PDF »
Long Peptide Vaccination Can Lead to Lethality through CD4+ T Cell-Mediated Cytokine Storm.
H. Kitamura, C. Sedlik, A. Jacquet, B. Zaragoza, M. Dusseaux, V. Premel, X. Sastre-Garau, and O. Lantz (2010)
J. Immunol. 185, 892-901
   Abstract »    Full Text »    PDF »
Immunotherapy Can Reject Intracranial Tumor Cells without Damaging the Brain despite Sharing the Target Antigen.
B. W. Bridle, J. Li, S. Jiang, R. Chang, B. D. Lichty, J. L. Bramson, and Y. Wan (2010)
J. Immunol. 184, 4269-4275
   Abstract »    Full Text »    PDF »
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.
H. E. Heslop, K. S. Slobod, M. A. Pule, G. A. Hale, A. Rousseau, C. A. Smith, C. M. Bollard, H. Liu, M.-F. Wu, R. J. Rochester, et al. (2010)
Blood 115, 925-935
   Abstract »    Full Text »    PDF »
A Novel Function of Heparan Sulfate in the Regulation of Cell-Cell Fusion.
C. D. O'Donnell and D. Shukla (2009)
J. Biol. Chem. 284, 29654-29665
   Abstract »    Full Text »    PDF »
Lineage-Specific T-Cell Responses to Cancer Mucosa Antigen Oppose Systemic Metastases without Mucosal Inflammatory Disease.
A. E. Snook, P. Li, B. J. Stafford, E. J. Faul, L. Huang, R. C. Birbe, A. Bombonati, S. Schulz, M. J. Schnell, L. C. Eisenlohr, et al. (2009)
Cancer Res. 69, 3537-3544
   Abstract »    Full Text »    PDF »
Naive Mouse Macrophages Become Activated following Recognition of L5178Y Lymphoma Cells via Concurrent Ligation of CD40, NKG2D, and CD18 Molecules.
I. N. Buhtoiarov, A. L. Rakhmilevich, L. L. Lanier, E. A. Ranheim, and P. M. Sondel (2009)
J. Immunol. 182, 1940-1953
   Abstract »    Full Text »    PDF »
IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes.
S. Kaneko, S. Mastaglio, A. Bondanza, M. Ponzoni, F. Sanvito, L. Aldrighetti, M. Radrizzani, S. La Seta-Catamancio, E. Provasi, A. Mondino, et al. (2009)
Blood 113, 1006-1015
   Abstract »    Full Text »    PDF »
Correlation of effector function with phenotype and cell division after in vitro differentiation of naive MART-1-specific CD8+ T cells.
J. G. Casado, O. DelaRosa, G. Pawelec, E. Peralbo, E. Duran, F. Barahona, R. Solana, and R. Tarazona (2009)
Int. Immunol. 21, 53-62
   Abstract »    Full Text »    PDF »
Role of Dendritic Cells in Enhancement of Herpes Simplex Virus Type 1 Latency and Reactivation in Vaccinated Mice.
K. R. Mott and H. Ghiasi (2008)
Clin. Vaccine Immunol. 15, 1859-1867
   Abstract »    Full Text »    PDF »
Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice.
A. Bai, E. Higham, H. N. Eisen, K. D. Wittrup, and J. Chen (2008)
PNAS 105, 13003-13008
   Abstract »    Full Text »    PDF »
CD4+CD25- T Cells Transduced to Express MHC Class I-Restricted Epitope-Specific TCR Synthesize Th1 Cytokines and Exhibit MHC Class I-Restricted Cytolytic Effector Function in a Human Melanoma Model.
A. Chhabra, L. Yang, P. Wang, B. Comin-Anduix, R. Das, N. G. Chakraborty, S. Ray, S. Mehrotra, H. Yang, C. L. Hardee, et al. (2008)
J. Immunol. 181, 1063-1070
   Abstract »    Full Text »    PDF »
Guanylyl Cyclase C-Induced Immunotherapeutic Responses Opposing Tumor Metastases Without Autoimmunity.
A. E. Snook, B. J. Stafford, P. Li, G. Tan, L. Huang, R. Birbe, S. Schulz, M. J. Schnell, M. Thakur, J. L. Rothstein, et al. (2008)
J Natl Cancer Inst 100, 950-961
   Abstract »    Full Text »    PDF »
HLA Class I Antigen Processing Machinery Component Expression and Intratumoral T-Cell Infiltrate as Independent Prognostic Markers in Ovarian Carcinoma.
L. Y. Han, M. S. Fletcher, D. L. Urbauer, P. Mueller, C. N. Landen, A. A. Kamat, Y. G. Lin, W. M. Merritt, W. A. Spannuth, M. T. Deavers, et al. (2008)
Clin. Cancer Res. 14, 3372-3379
   Abstract »    Full Text »    PDF »
Targeting AKT Signaling Sensitizes Cancer to Cellular Immunotherapy.
P. S. Hahnel, S. Thaler, E. Antunes, C. Huber, M. Theobald, and M. Schuler (2008)
Cancer Res. 68, 3899-3906
   Abstract »    Full Text »    PDF »
TLR9 engagement on CD4 T lymphocytes represses {gamma}-radiation-induced apoptosis through activation of checkpoint kinase response elements.
L. Zheng, N. Asprodites, A. H. Keene, P. Rodriguez, K. D. Brown, and E. Davila (2008)
Blood 111, 2704-2713
   Abstract »    Full Text »    PDF »
Low-dose radioimmuno-therapy of cancer.
M. Pollycove and L. E Feinendegen (2008)
Human and Experimental Toxicology 27, 169-175
   Abstract »    PDF »
An immune escape screen reveals Cdc42 as regulator of cancer susceptibility to lymphocyte-mediated tumor suppression.
C. A. Marques, P. S. Hahnel, C. Wolfel, S. Thaler, C. Huber, M. Theobald, and M. Schuler (2008)
Blood 111, 1413-1419
   Abstract »    Full Text »    PDF »
A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer.
E. Kieback, J. Charo, D. Sommermeyer, T. Blankenstein, and W. Uckert (2008)
PNAS 105, 623-628
   Abstract »    Full Text »    PDF »
Rapid reversal of interleukin-6-dependent epithelial invasion in a mouse model of microbially induced colon carcinoma.
T. Poutahidis, K. M. Haigis, V. P. Rao, P. R. Nambiar, C. L. Taylor, Z. Ge, K. Watanabe, A. Davidson, B. H. Horwitz, J. G. Fox, et al. (2007)
Carcinogenesis 28, 2614-2623
   Abstract »    Full Text »    PDF »
Cross-presentation of glycolipid from tumor cells loaded with {alpha}-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells.
K. Shimizu, Y. Kurosawa, M. Taniguchi, R. M. Steinman, and S.-i. Fujii (2007)
J. Exp. Med. 204, 2641-2653
   Abstract »    Full Text »    PDF »
The Endothelial Cell-Produced Antiangiogenic Cytokine Vascular Endothelial Growth Inhibitor Induces Dendritic Cell Maturation.
F. Tian, S. Grimaldo, M. Fugita, J. Cutts, N. L. Vujanovic, and L.-Y. Li (2007)
J. Immunol. 179, 3742-3751
   Abstract »    Full Text »    PDF »
Tumor-Derived Chemokine MCP-1/CCL2 Is Sufficient for Mediating Tumor Tropism of Adoptively Transferred T Cells.
C. E. Brown, R. P. Vishwanath, B. Aguilar, R. Starr, J. Najbauer, K. S. Aboody, and M. C. Jensen (2007)
J. Immunol. 179, 3332-3341
   Abstract »    Full Text »    PDF »
Brain Microenvironment Promotes the Final Functional Maturation of Tumor-Specific Effector CD8+ T Cells.
F. Masson, T. Calzascia, W. Di Berardino-Besson, N. de Tribolet, P.-Y. Dietrich, and P. R. Walker (2007)
J. Immunol. 179, 845-853
   Abstract »    Full Text »    PDF »
The Loss of Telomerase Activity in Highly Differentiated CD8+CD28-CD27- T Cells Is Associated with Decreased Akt (Ser473) Phosphorylation.
F. J. Plunkett, O. Franzese, H. M. Finney, J. M. Fletcher, L. L. Belaramani, M. Salmon, I. Dokal, D. Webster, A. D. G. Lawson, and A. N. Akbar (2007)
J. Immunol. 178, 7710-7719
   Abstract »    Full Text »    PDF »
Induction of Tolerance in CD8+ T Cells to a Transgenic Autoantigen Expressed in the Liver Does Not Require Cross-Presentation.
J. Morimoto, X. Tan, R. M. Teague, C. Ohlen, and P. D. Greenberg (2007)
J. Immunol. 178, 6849-6860
   Abstract »    Full Text »    PDF »
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy.
R. Spisek, A. Kukreja, L.-C. Chen, P. Matthews, A. Mazumder, D. Vesole, S. Jagannath, H. A. Zebroski, A. J.G. Simpson, G. Ritter, et al. (2007)
J. Exp. Med. 204, 831-840
   Abstract »    Full Text »    PDF »
CpG oligodeoxynucleotides allow for effective adoptive T-cell therapy in chronic retroviral infection.
A. R. M. Kraft, F. Krux, S. Schimmer, C. Ohlen, P. D. Greenberg, and U. Dittmer (2007)
Blood 109, 2982-2984
   Abstract »    Full Text »    PDF »
Tumor Antigen-Specific T-Cell Expansion Is Greatly Facilitated by In vivo Priming.
Y. Dang, K. L. Knutson, V. Goodell, C. dela Rosa, L. G. Salazar, D. Higgins, J. Childs, and M. L. Disis (2007)
Clin. Cancer Res. 13, 1883-1891
   Abstract »    Full Text »    PDF »
Enhanced Antitumor Responses Elicited by Combinatorial Protein Transfer of Chemotactic and Costimulatory Molecules.
S. Liu, D. R. Breiter, G. Zheng, and A. Chen (2007)
J. Immunol. 178, 3301-3306
   Abstract »    Full Text »    PDF »
Inactivated Sendai Virus Particles Eradicate Tumors by Inducing Immune Responses through Blocking Regulatory T Cells.
M. Kurooka and Y. Kaneda (2007)
Cancer Res. 67, 227-236
   Abstract »    Full Text »    PDF »
Engineering Antitumor Immunity by T-Cell Adoptive Immunotherapy.
S. R. Riddell (2007)
Hematology 2007, 250-256
   Abstract »    Full Text »    PDF »
Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches.
J. Greiner, M. Schmitt, L. Li, K. Giannopoulos, K. Bosch, A. Schmitt, K. Dohner, R. F. Schlenk, J. R. Pollack, H. Dohner, et al. (2006)
Blood 108, 4109-4117
   Abstract »    Full Text »    PDF »
Spontaneous CD8 T Cell Responses against the Melanocyte Differentiation Antigen RAB38/NY-MEL-1 in Melanoma Patients.
S. M. Walton, M. Gerlinger, O. de la Rosa, N. Nuber, A. Knights, A. Gati, M. Laumer, L. Strauss, C. Exner, N. Schafer, et al. (2006)
J. Immunol. 177, 8212-8218
   Abstract »    Full Text »    PDF »
Preclinical pharmacokinetics, tissue distribution, and antitumor activity of a folate-hapten conjugate-targeted immunotherapy in hapten-immunized mice.
Y. Lu, L.-C. Xu, N. Parker, E. Westrick, J. A. Reddy, M. Vetzel, P. S. Low, and C. P. Leamon (2006)
Mol. Cancer Ther. 5, 3258-3267
   Abstract »    Full Text »    PDF »
Random migration precedes stable target cell interactions of tumor-infiltrating T cells.
P. Mrass, H. Takano, L. G. Ng, S. Daxini, M. O. Lasaro, A. Iparraguirre, L. L. Cavanagh, U. H. von Andrian, H. C.J. Ertl, P. G. Haydon, et al. (2006)
J. Exp. Med. 203, 2749-2761
   Abstract »    Full Text »    PDF »
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes.
R. A. Morgan, M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, et al. (2006)
Science 314, 126-129
   Abstract »    Full Text »    PDF »
Different Lineages of P1A-Expressing Cancer Cells Use Divergent Modes of Immune Evasion for T-Cell Adoptive Therapy.
X.-F. Bai, J.-Q. Liu, P. S. Joshi, L. Wang, L. Yin, J. Labanowska, N. Heerema, P. Zheng, and Y. Liu (2006)
Cancer Res. 66, 8241-8249
   Abstract »    Full Text »    PDF »
Antigen Chemically Coupled to the Surface of Liposomes Are Cross-Presented to CD8+ T Cells and Induce Potent Antitumor Immunity.
M. Taneichi, H. Ishida, K. Kajino, K. Ogasawara, Y. Tanaka, M. Kasai, M. Mori, M. Nishida, H. Yamamura, J. Mizuguchi, et al. (2006)
J. Immunol. 177, 2324-2330
   Abstract »    Full Text »    PDF »
Update on Immunotherapy for Melanoma.
A. Ribas (2006)
J Natl Compr Canc Netw 4, 687-694
   Abstract »    PDF »
Immune Escape Associated with Functional Defects in Antigen-Processing Machinery in Head and Neck Cancer..
R. L. Ferris, T. L. Whiteside, and S. Ferrone (2006)
Clin. Cancer Res. 12, 3890-3895
   Abstract »    Full Text »    PDF »
Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic Peptide..
N. Papo, D. Seger, A. Makovitzki, V. Kalchenko, Z. Eshhar, H. Degani, and Y. Shai (2006)
Cancer Res. 66, 5371-5378
   Abstract »    Full Text »    PDF »
Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector..
H. Mima, S. Yamamoto, M. Ito, R. Tomoshige, Y. Tabata, K. Tamai, and Y. Kaneda (2006)
Mol. Cancer Ther. 5, 1021-1028
   Abstract »    Full Text »    PDF »
Role of Antigen-Processing Machinery in the In Vitro Resistance of Squamous Cell Carcinoma of the Head and Neck Cells to Recognition by CTL.
A. Lopez-Albaitero, J. V. Nayak, T. Ogino, A. Machandia, W. Gooding, A. B. DeLeo, S. Ferrone, and R. L. Ferris (2006)
J. Immunol. 176, 3402-3409
   Abstract »    Full Text »    PDF »
Ex vivo Detectable Human CD8 T-Cell Responses to Cancer-Testis Antigens.
P. Baumgaertner, N. Rufer, E. Devevre, L. Derre, D. Rimoldi, C. Geldhof, V. Voelter, D. Lienard, P. Romero, and D. E. Speiser (2006)
Cancer Res. 66, 1912-1916
   Abstract »    Full Text »    PDF »
Embryonic Stem Cell-Derived Dendritic Cells Expressing Glypican-3, a Recently Identified Oncofetal Antigen, Induce Protective Immunity against Highly Metastatic Mouse Melanoma, B16-F10.
Y. Motomura, S. Senju, T. Nakatsura, H. Matsuyoshi, S. Hirata, M. Monji, H. Komori, D. Fukuma, H. Baba, and Y. Nishimura (2006)
Cancer Res. 66, 2414-2422
   Abstract »    Full Text »    PDF »
Selective Targeting of Antitumor Immune Responses with Engineered Live-Attenuated Listeria monocytogenes.
K. Yoshimura, A. Jain, H. E. Allen, L. S. Laird, C. Y. Chia, S. Ravi, D. G. Brockstedt, M. A. Giedlin, K. S. Bahjat, M. L. Leong, et al. (2006)
Cancer Res. 66, 1096-1104
   Abstract »    Full Text »    PDF »
De novo Induction of a Cancer/Testis Antigen by 5-Aza-2'-Deoxycytidine Augments Adoptive Immunotherapy in a Murine Tumor Model.
Z. S. Guo, J. A. Hong, K. R. Irvine, G. A. Chen, P. J. Spiess, Y. Liu, G. Zeng, J. R. Wunderlich, D. M. Nguyen, N. P. Restifo, et al. (2006)
Cancer Res. 66, 1105-1113
   Abstract »    Full Text »    PDF »
The In vivo Expansion Rate of Properly Stimulated Transferred CD8+ T Cells Exceeds That of an Aggressively Growing Mouse Tumor.
L. N. Hwang, Z. Yu, D. C. Palmer, and N. P. Restifo (2006)
Cancer Res. 66, 1132-1138
   Abstract »    Full Text »    PDF »
Non-Small-Cell Lung Cancer Vaccine Therapy: A Concise Review.
D. O'Mahony, S. Kummar, and M. E. Gutierrez (2005)
J. Clin. Oncol. 23, 9022-9028
   Abstract »    Full Text »    PDF »
Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies.
K. D. Lute, K. F. May Jr, P. Lu, H. Zhang, E. Kocak, B. Mosinger, C. Wolford, G. Phillips, M. A. Caligiuri, P. Zheng, et al. (2005)
Blood 106, 3127-3133
   Abstract »    Full Text »    PDF »
Fusokine Interleukin-2/Interleukin-18, a Novel Potent Innate and Adaptive Immune Stimulator with Decreased Toxicity.
B. Acres, M. Gantzer, C. Remy, N. Futin, N. Accart, O. Chaloin, J. Hoebeke, J.-M. Balloul, and S. Paul (2005)
Cancer Res. 65, 9536-9546
   Abstract »    Full Text »    PDF »
Inhibition of NK Cell Activity through TGF-{beta}1 by Down-Regulation of NKG2D in a Murine Model of Head and Neck Cancer.
S. Dasgupta, M. Bhattacharya-Chatterjee, B. W. O'Malley Jr, and S. K. Chatterjee (2005)
J. Immunol. 175, 5541-5550
   Abstract »    Full Text »    PDF »
Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy.
T. Zhang, B. A. Lemoi, and C. L. Sentman (2005)
Blood 106, 1544-1551
   Abstract »    Full Text »    PDF »
In Vivo Hydrodynamic Delivery of cDNA Encoding IL-2: Rapid, Sustained Redistribution, Activation of Mouse NK Cells, and Therapeutic Potential in the Absence of NKT Cells.
J. R. Ortaldo, R. T. Winkler-Pickett, E. W. Bere Jr, M. Watanabe, W. J. Murphy, and R. H. Wiltrout (2005)
J. Immunol. 175, 693-699
   Abstract »    Full Text »    PDF »
A Novel Treatment for Ocular Tumors Using Membrane FasL Vesicles to Activate Innate Immunity and Terminate Immune Privilege.
M. S. Gregory, S. Koh, E. Huang, R. R. Saff, A. Marshak-Rothstein, S. Mukai, and B. R. Ksander (2005)
Invest. Ophthalmol. Vis. Sci. 46, 2495-2502
   Abstract »    Full Text »    PDF »
Artificial Antigen-Presenting Cells Transduced with Telomerase Efficiently Expand Epitope-Specific, Human Leukocyte Antigen-Restricted Cytotoxic T Cells.
J. Dupont, J.-B. Latouche, C. Ma, and M. Sadelain (2005)
Cancer Res. 65, 5417-5427
   Abstract »    Full Text »    PDF »
Recruiting dendritic cells to improve antibody therapy of cancer.
K. M. Dhodapkar and M. V. Dhodapkar (2005)
PNAS 102, 6243-6244
   Full Text »    PDF »
Unveiling the Mechanisms of Cell-Cell Fusion.
E. H. Chen and E. N. Olson (2005)
Science 308, 369-373
   Abstract »    Full Text »    PDF »
Stat3 Activity in Melanoma Cells Affects Migration of Immune Effector Cells and Nitric Oxide-Mediated Antitumor Effects.
L. Burdelya, M. Kujawski, G. Niu, B. Zhong, T. Wang, S. Zhang, M. Kortylewski, K. Shain, H. Kay, J. Djeu, et al. (2005)
J. Immunol. 174, 3925-3931
   Abstract »    Full Text »    PDF »
Protective CD8 T Cell Immunity Triggered by CpG-Protein Conjugates Competes with the Efficacy of Live Vaccines.
A. Heit, F. Schmitz, M. O'Keeffe, C. Staib, D. H. Busch, H. Wagner, and K. M. Huster (2005)
J. Immunol. 174, 4373-4380
   Abstract »    Full Text »    PDF »
The Evolution of Antibodies into Versatile Tumor-Targeting Agents.
M. Z. Lin, M. A. Teitell, and G. J. Schiller (2005)
Clin. Cancer Res. 11, 129-138
   Abstract »    Full Text »    PDF »
Finding a Place for Tumor-specific T Cells in Targeted Cancer Therapy.
S. R. Riddell (2004)
J. Exp. Med. 200, 1533-1537
   Abstract »    Full Text »    PDF »

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882